Scenesse Approval Buoys Clinuvel As It Fights Retrophin
This article was originally published in PharmAsia News
The Australian firm Clinuvel sees good prospects for its dermatology product Scenesse, but at the same time is fighting off unwanted acquisition advances from a corporate suitor.
You may also be interested in...
European Backing For AstraZeneca’s Olaparib Bolsters Barriers To Pfizer
Europe’s top medicines advisory panel, the CHMP, also recommended for approval Clinuvel’s Scenesse for severe intolerance to sunlight, Pfizer’s new combination menopausal symptom therapy Duavive, and Baxter’s new hemophilia B therapy Rixubis.
Cynata Sets Stage For Global Fujifilm Cell Therapy Deal
Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.
INTERVIEW: Business Is Personal For Avita CEO Kelliher
As a former war correspondent on the battlefields of the Balkans, Afghanistan and Iraq, new Avita Medical chief executive Adam Kelliher can claim to have an up-close understanding of the types of injuries that his regenerative medicine company’s lead product is designed to heal.